Pharmaceutical

Janssen seeks EMA authorisation for urothelial cancer treatment

Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.

Sep 11, 2023 - 20:00
Janssen seeks EMA authorisation for urothelial cancer treatment
Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.
Read the original article

Tags:

Previous Article

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Next Article

Alexion and Verge enter AI-powered drug discovery deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: What to know about Sarepta’s upcoming data on its Duchenne gene therapy

STAT+: What to know about Sarepta’s upcoming data on it...

Oct 30, 2023

Iovance looks to advance its non-small cell lung cancer therapy

Iovance looks to advance its non-small cell lung cancer...

Jul 11, 2023

Speciality Chemicals for the Pharmaceutical Industry

Speciality Chemicals for the Pharmaceutical Industry

Oct 2, 2024